Here are the 424B prospectus supplements from Bone Biologics Corp (BBLG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLG filings page.
Bone Biologics Corporation is registering up to 6,464,792 shares of common stock for resale by selling stockholders, all issuable upon exercise of outstanding warrants from a July 9, 2026 private placement and related placement agent warrants. The company will not receive proceeds from resale of these shares, but could receive approximately $6.2 million if all warrants are exercised for cash.
Shares outstanding were 1,810,380 as of July 16, 2026 and would be 8,275,172 assuming full warrant exercise. The registered shares equal about 357% of current outstanding stock, and large resales could pressure the share price. Bone Biologics is a clinical-stage medical device company developing NB1, a NELL-1/demineralized bone matrix fusion device for lumbar spinal fusion, with an ongoing pilot study in up to 30 subjects in Australia. The company has a going concern explanatory paragraph in its 2025 audit opinion and relies on additional capital, including potential warrant exercise proceeds, to fund trials, patents, and working capital.
Bone Biologics Corporation is offering up to $1,064,000 of common stock through an at‑the‑market sales agreement with H.C. Wainwright & Co., enabling periodic sales into the Nasdaq market. As of March 13, 2026, the company had previously issued 195,722 shares for gross proceeds of $1,678,036 under the same program.
The prospectus supplement states 1,795,260 shares outstanding prior to this offering (as of March 13, 2026) and models up to 2,626,510 shares outstanding after this offering assuming sale of 831,250 shares at $1.28 per share. Net proceeds are designated to fund clinical trials, maintain and extend the patent portfolio, and for working capital. The filing discloses an auditor going concern explanatory paragraph and highlights that additional capital will be required to continue operations.